Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

Project: Research project

Project Details

StatusFinished
Effective start/end date1/26/17 → 1/26/20

Funding

  • Merck Sharp & Dohme Corporation (Prot #MK-3475-183)